James R. Tobin, Director at TransMedics Group, Inc. (TMDX), sold 27,980 shares at $105.70 ($3.0M) on 2024-05-01, disclosed to the SEC on 2024-05-03.
Scheduled sale ($3.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.70 | 11,236 | $1.2M | 40.0% |
| 2 | $105.70 | 11,236 | $1.2M | 40.0% |
| 3 | $106.89 | 1,704 | $182K | 6.1% |
| 4 | $106.89 | 1,704 | $182K | 6.1% |
| 5 | $108.47 | 100 | $11K | 0.4% |
| 6 | $110.00 | 2,000 |
| $220K |
| 7.4% |
| Total | $106.16 avg | 27,980 | $3.0M | 100% |
| Filing → |
| TMDX | SELL | 2024-03-05 | $2.2M | — | Filing → |
| TMDX | SELL | 2023-11-29 | $701K | — | Filing → |
| TMDX | SELL | 2023-02-27 | $751K | — | Filing → |